Flagship’s Quotient names co-founder Campbell CSO

Flagship-backed Quotient Therapeutics Inc. named Peter Campbell CSO. Campbell, one of Quotient’s academic co-founders, is head of cancer, aging and somatic mutation and senior group leader at the Wellcome Sanger Institute. Quotient is using cutting-edge sequencing tech to identify actionable somatic mutations linked to disease states.

Cell and gene therapy company Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) hired Adrian Kilcoyne to succeed Mark Frattini as CMO. Kilcoyne was CMO and head of R&D at Celularity Inc. (NASDAQ:CELU). Frattini is leaving to pursue other opportunities. ...